Repligen Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RGEN research report →
Range $160 – $225
Price Chart
About the company
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing.
- CEO
- Olivier Loeillot
- IPO
- 1986
- Employees
- 2,000
- HQ
- Waltham, MA, US
AI snapshot
Six angles, distilled from the data.
The stock is still in a long-term uptrend, but it has pulled back from the upper end of its 52-week range. It remains above the 200-day average at 145.62, while the 50-day average at 177.19 sits above the last close, signaling a consolidation phase after a strong run.
Street sentiment stays constructive, with a Buy consensus and a 198 median target versus the last close. Recent calls have leaned higher rather than softer, including target hikes to 225 at Barclays, 200 at RBC Capital, and 180 at Canaccord, even as several firms simply reiterated prior ratings.
The company has a strong beat pattern, with 7 of the last 8 quarters topping EPS estimates. Next-year EPS is modeled at 2.6521, a sharp reset from the trailing loss, so shareholders should watch whether revenue growth and margin recovery keep pace with that step-up.
Recent insider activity leans to net selling, led by CEO Olivier Loeillot, while most of the other filings are award, exempt, or in-kind transactions that are less informative. The pattern does not show notable insider accumulation, so the signal is more cautionary than supportive.
Profitability is mixed but improving at the operating level: gross margin is 53.8% and operating margin is 8.14%, while net margin remains negative at -1.47%. Revenue grew 10.9% year over year, and the balance sheet is solid with $767.6 million in cash versus $689.9 million of debt.
RGEN sits in the premium end of life sciences tools, where recurring bioprocess demand and product breadth can support higher multiples than broader medical supplies names. At 91.01 times earnings, the valuation already prices in a durable recovery and execution upside.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $10.47B
- P/E
- -780.05
- Fwd P/E
- 78.98
- PEG
- 0.98
- P/S
- 13.00
- P/B
- 4.43
- EV/EBITDA
- 82.92
- Div Yield
- 0.00%
- Gross Margin
- 51.05%
- Op Margin
- 2.35%
- Net Margin
- -1.47%
- ROE
- -0.56%
- ROIC
- -0.96%
Latest fiscal year · YoY change
- Revenue
- $738.26M+16.4%
- Gross Profit
- $347.62M+26.6%
- Op Income
- $59.58M
- Net Income
- $48.89M+291.6%
- EPS
- $0.87+289.1%
- OCF Growth
- -33.1%
- FCF Growth
- -34.1%
- 52W High
- $198.87
- 52W Low
- $100.99
- 50D MA
- $177.16
- 200D MA
- $145.74
- Beta
- 1.12
- RSI (14)
- 43
- Avg Volume
- 1.17M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Repligen posted a record Q3 with $209 million of revenue, raised full-year guidance, and said BioLife and improving equipment orders should support stronger growth into 2027.· October 27, 2026
- Record Q3 revenue of $209 million, with 11% reported growth and 12.5% organic growth.
- Adjusted operating margin expanded 170 basis points to 15.9%, while adjusted EPS rose to $0.53 from $0.46.
- BioLife closed in October and is expected to add about $24 million in Q4 revenue; management now sees 2026 revenue of $844 million to $852 million.
- Capital equipment orders were up mid-teens year over year and Q3 was the highest capital equipment order quarter in 5 years, but revenue recognition is mostly shifting into 2027.
- Management lifted full-year growth expectations across multiple franchises, including chromatography at 30%+ and analytics at 30%+.
Repligen reported third-quarter revenue of $209 million, up 11% year over year or 12.5% organically. Adjusted gross profit was $111 million and adjusted gross margin was 53%, down 30 basis points year over year, with year-to-date gross margin up 140 basis points. Adjusted income from operations was $33 million, up 24% year over year, and adjusted operating margin was 15.9%, up 170 basis points. Adjusted EBITDA was $44 million, or a 20.9% margin. Adjusted net income was $30 million, up 16%, and adjusted diluted EPS was $0.53 versus $0.46 a year ago. Cash, cash equivalents, and marketable securities were $863 million at quarter end, up $53 million sequentially. Full-year 2026 guidance was raised to revenue of $844 million to $852 million, or 14.5% to 15.5% reported growth and 12% to 13% organic growth, including about $24 million from BioLife, with adjusted EPS guided to $2.05 to $2.09. Management also expects adjusted operating income of $135 million to $139 million, adjusted operating margin of 16.0% to 16.3%, and gross margin expansion of 110 to 160 basis points for the year.
Olivier Loeillot framed the quarter as a proof point that Repligen is outpacing a recovering market, highlighting broad-based strength in proteins, chromatography, consumables, and services. He was notably upbeat about BioLife, saying the combined platform strengthens the cell therapy opportunity and that management is even more confident in the deal rationale after visiting the business. He also emphasized improving order trends in capital equipment, a stronger 2027 backlog, and strategic initiatives in Asia and on-shoring as future growth drivers.
Jason Garland focused on the mechanics behind the guidance raise and margin profile. He cited 53% adjusted gross margin, 15.9% adjusted operating margin, 20.9% adjusted EBITDA margin, and $863 million of quarter-end cash, then noted about $550 million of cash was deployed in October for BioLife, leaving pro forma cash above $300 million. He said BioLife is expected to be slightly dilutive in Q4 because Repligen will recognize nearly a full quarter of expenses but less than a full quarter of revenue, while still being at least $0.05 accretive in 2027. He also said CapEx should run at about 3% to 4% of 2026 revenue and that the company plans to keep investing in growth, IT modernization, AI, and manufacturing automation.
Analysts focused on the BioLife integration cadence, the weak revenue conversion in filtration and equipment despite stronger orders, and how to think about 2027 visibility. Management said most near-term BioLife synergies are already captured on public company and leadership costs, while longer-term improvements will come from lower scrap rates and revenue synergies; they also reiterated at least $0.05 of 2027 accretion. On equipment, management said orders were the highest in 5 years, but customers are pushing deliveries into 2027 and decision velocity has not fully improved yet. Questions also centered on on-shoring, biosimilars, and analytics attachment rates, with management saying on-shoring appears later than expected but could ramp next year and beyond, and that 75% to 80% of systems sold now include FlowVPX attachments.
The call showed broad operating momentum: record revenue, margin expansion, stronger orders, and raised guidance. Management sounded increasingly confident that BioLife, China growth, analytics adoption, and an eventual equipment rebound could all add to growth in 2027 and beyond.
The biggest near-term risk remains timing: equipment revenue is still lagging orders, and management said most of the new backlog will likely convert in 2027 rather than 2026. Filtration was weaker than expected due to ATF, customer timing, and the PolyMem divestiture, while BioLife will add only a partial-quarter contribution in Q4 and is still being integrated.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 95.4%
- Shares Outstanding
- 63.92M
- Float Shares
- 60.96M
of shares held by institutions
500 13F filers
Buy/sell ratio 0.75. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for RGEN, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Lisa C. McClainHouse · MI09 | Sell | Oct 30, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Oct 31, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Oct 30, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Jul 22, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Jun 11, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Jun 17, 25 | Filing → |
| Jefferson ShreveHouse · IN06 | Sell | Apr 7, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Apr 11, 22 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Feb 17, 22 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jan 20, 22 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jan 11, 22 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 7.35M | ▲ 4.02M |
| Blackrock, Inc. | 5.73M | ▲ 341.79K |
| Vanguard Group Inc | 4.99M | ▼ 50.25K |
| United Capital Financial Advisors, LLC | 2.79M | ▼ 612 |
| Vanguard Capital Management LLC | 2.44M | ▲ 31.57K |
| Vanguard Portfolio Management LLC | 2.27M | ▼ 40.95K |
| Invesco Ltd. | 2.13M | ▲ 746.82K |
| Price T Rowe Associates Inc | 2.03M | ▲ 277.96K |
| Massachusetts Financial Services Co | 2.03M | ▲ 411.97K |
| State Street Corp | 1.85M | ▲ 49.02K |
| Ameriprise Financial Inc | 1.69M | ▲ 112.83K |
| Maverick Capital Ltd | 1.42M | ▼ 567.07K |
Held by 593 ETFs
Biggest fund positions in RGEN by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 6, 26 | Douglass Brian Robb | other | 700 |
| Oct 6, 26 | Douglass Brian Robb | other | 675 |
| Oct 5, 26 | Loeillot Olivier | other | 4,202 |
| Oct 5, 26 | Loeillot Olivier | sell | 4,202 |
| Oct 5, 26 | Loeillot Olivier | sell | 1,333 |
| Oct 5, 26 | Loeillot Olivier | other | 4,202 |
| Oct 2, 26 | Loeillot Olivier | other | 1,248 |
| Sep 25, 26 | Garland Jason K | other | 421 |
| Sep 24, 26 | Loeillot Olivier | other | 8,404 |
| Sep 24, 26 | Loeillot Olivier | other | 4,542 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RGEN coverage
Recent articles, reports, and earnings notes.

Repligen (RGEN): Bioprocess Growth vs. Rich Valuation
Repligen is showing strong momentum in chromatography, proteins, and analytics, but the stock already prices in a robust recovery. The report supports a Hold as growth improves while valuation remains demanding.

Repligen Corporation (RGEN) Slumps 19.9% After-Hours
Repligen Corporation (RGEN) slumps sharply in after-hours trading after a strong quarter and raised guidance. The move appears tied more to a recent $1.0B convertible note deal and risk repricing than to a fresh earnings miss, leaving investors to watch the next regular session for confirmation.

Intuitive Surgical’s selloff looks overdone if Da Vinci 5 is the real story
Intuitive Surgical just got hit like the growth story broke, yet the quarter said the opposite. Revenue rose 19%, procedures stayed double-digit, and da Vinci 5 placements kept climbing, which makes this look more like an expectations reset than a business problem.
Want a deeper read on RGEN?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Repligen Corporation (RGEN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 18
3,054 Shares in Repligen Corporation $RGEN Bought by Ethic Inc.
defenseworld.net · Nov 16
AMG TimesSquare Small Cap Growth Fund Q3 2026 Portfolio Activity
seekingalpha.com · Nov 15
Alger Mid Cap 40 ETF Q3 2026 Portfolio Review
seekingalpha.com · Nov 12
Voya Small Cap Growth Strategy Q3 2026 Contributors And Detractors
seekingalpha.com · Nov 12
Repligen: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 5
Repligen Corporation to Present at Jefferies Global Healthcare Conference
globenewswire.com · Nov 4
Baron SMID Cap ETF Q3 2026 Contributors And Detractors
seekingalpha.com · Nov 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 21, 2026 · Live quote · Not investment advice